Skip to content

Poor Sleep and Inflammation in HIV-Infected Adults

Impact of Poor Sleep on Inflammation and the Adenosine Signaling Pathway in HIV Infection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03848325
Acronym
SASH
Enrollment
20
Registered
2019-02-20
Start date
2020-11-09
Completion date
2022-07-31
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1-infection, Inflammation, Sleep Deprivation

Keywords

adenosine

Brief summary

People living with HIV (PLWH) often have poor sleep, which may put them at a higher risk for many chronic diseases, including cardiovascular disease. One of the mechanisms by which this may occur is via chronic inflammation and endothelial dysfunction. Adenosine plays an important role in sleep homeostasis, with levels increasing in the CSF in response to sleep deprivation and falling with sleep. Peripherally, adenosine, via its signaling pathway, plays an important role in immunoregulation by suppressing the inflammatory response. PLWH, even on antiretroviral therapy, have suppressed peripheral adenosine levels which are predictive of adverse cardiovascular outcomes. The hypothesis underlying this study is that acute sleep deprivation in PLWH does not result in a compensatory increase in extracellular adenosine and its signaling peripherally, and this failure to appropriately compensate, leads to an increase in systemic inflammation and endothelial dysfunction.

Detailed description

People living with HIV infection (PLWH) are known to be at higher risk of cardiovascular disease and also have a higher prevalence of poor sleep than people who do not have HIV infection. Understanding the underlying mechanisms for the elevated risk of cardiovascular disease in PLWH is important to developing novel strategies to mitigate this risk. Poor sleep has been postulated to mediate some of the elevated cardiovascular risk in PLWH given the high prevalence of poor sleep in PLWH and the epidemiologic association of poor sleep with adverse cardiovascular outcomes among people who do not have HIV infection. However, the mechanisms by which PLWH may be more sensitive to sleep loss from a cardiovascular standpoint are unclear. One potential explanation for any elevated sensitivity would be via alterations in the adenosine signaling pathway. Changes in extracellular adenosine levels in the brain and central nervous system play an important homeostatic role in sleep-wake regulation. Sleep deprivation results in a rise in extracellular adenosine levels while sleep itself leads to a rapid decline in levels. Peripheral adenosine signaling is a central feature of immunoregulation, primarily through its effects on inflammatory cytokine expression and lymphocyte adenosine receptor expression. PLWH tend to have a suppressed level of peripheral adenosine signaling and this level of suppression predicts risk of cardiovascular disease. The purpose of this study is to explore the impact of acute sleep deprivation among PLWH on measures of inflammation and endothelial function and to assess the extent to which any changes may be explained by alterations in peripheral adenosine signaling. The study will enroll 40 PLWH, age 18-75, who have been on ART for greater than 48 weeks. Screening with questionnaires, actigraphy and polysomnography will eliminate individuals with underlying chronic sleep abnormalities. A prior night of polysomnography in the sleep lab will also habituate subjects to sleeping while monitored in the sleep lab. Participants will arrive in the sleep laboratory in the evening and be allowed to sleep for 8 hours timed to their usual sleep patterns. On waking, participants will provide a urine sample that will be assayed for adenosine and adenosine metabolites. Blood will be drawn to measure markers of inflammation as well as markers of activation of the peripheral adenosine signaling system. Endothelial function will be assessed using flow mediated dilation. Participants will be kept awake for the subsequent 24 hours including the 8 hour normal sleep period. On the second morning, subjects will again provide urine and blood samples for the same bioassays described above and then undergo repeat assessment of endothelial function.

Interventions

BEHAVIORALSleep deprivation

Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Technicians processing biospecimens will be blinded to whether samples were collected on Day 1 or Day 2. Similarly, the assessor of brachial artery reactivity measurements will be blinded to whether ultrasound images were collected on Day 1 or Day 2.

Intervention model description

All participants will undergo one night of normal sleep (Night 1) followed by a subsequent night (Night 2) of sleep deprivation. Outcomes will be assessed the morning (Day 1 and Day 2) after each condition.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* HIV positive * On continuous anti-retroviral therapy regimen for at least 48 weeks * CD4+ cell count greater than or equal to 200 cells/mm\^3

Exclusion criteria

* Irregular or insufficient habitual sleep patterns * Severe advanced or delayed sleep phase * Primary sleep disorder * Autoimmune disorder * Use of immunosuppressant medications * Use of medications impacting adenosine pathway * Heavy caffeine use * Active alcohol or drug abuse * Elevated risk of adverse health effects from sleep deprivation (e.g., bipolar disorder, epilepsy, or suicidal ideation in the past 6 months) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Soluble CD14Baseline sleep replete state and after 24 hours of sleep deprivationPlasma concentration of soluble CD14
IL6Baseline sleep replete state and after 24 hours of sleep deprivationPlasma concentration of interleukin-6
Soluble CD163Baseline sleep replete state and after 24 hours of sleep deprivationPlasma concentration of soluble CD163

Secondary

MeasureTime frameDescription
Monocyte Expression of IL6Baseline sleep replete state and after 24 hours of sleep deprivationPercentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6
Flow Mediated Brachial Artery DilationBaseline sleep replete state and after 24 hours of sleep deprivationPercent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point.
Monocyte Expression of TNF-alphaBaseline sleep replete state and after 24 hours of sleep deprivationPercentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha
CD4+ T-cell Expression of HLA-DR and CD38Baseline sleep replete state and after 24 hours of sleep deprivationPercentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38
CD8+ T-cell Expression of HLA-DR and CD38Baseline sleep replete state and after 24 hours of sleep deprivationPercentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38

Other

MeasureTime frameDescription
Urine 3'5'-cAMPBaseline sleep replete state and after 24 hours of sleep deprivationUrine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine
CD8+ T-cell Expression of CD39 and/or CD73Baseline sleep replete state and after 24 hours of sleep deprivationPercentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73
Plasma InosineBaseline sleep replete state and after 24 hours of sleep deprivationPlasma inosine concentration
Plasma AdenosineBaseline sleep replete state and after 24 hours of sleep deprivationPlasma adenosine concentration
CD4+ T-cell Expression of CD39 and/or CD73Baseline sleep replete state and after 24 hours of sleep deprivationPercentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73

Countries

United States

Participant flow

Participants by arm

ArmCount
Baseline (Sleep Repletion) Followed by Sleep Deprivation
An 8 hour opportunity for sleep followed by outcome assessment the next morning and then 24 hour sleep deprivation followed by repeat outcome assessment.
20
Total20

Baseline characteristics

CharacteristicBaseline (Sleep Repletion) Followed by Sleep Deprivation
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
5 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
Age, Continuous61.1 years
STANDARD_DEVIATION 9.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
10 Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
1 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

IL6

Plasma concentration of interleukin-6

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Population: All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed.

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationIL6Baseline (Sleep repletion)4.46 pg/mLStandard Deviation 2.06
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationIL6After sleep deprivation4.27 pg/mLStandard Deviation 1.14
Primary

Soluble CD14

Plasma concentration of soluble CD14

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationSoluble CD14Baseline (Sleep repletion)1290 ng/mLStandard Deviation 405
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationSoluble CD14After sleep deprivation1196 ng/mLStandard Deviation 533
Primary

Soluble CD163

Plasma concentration of soluble CD163

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Population: All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed.

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationSoluble CD163Baseline (Sleep repletion)359 ng/mLStandard Deviation 231
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationSoluble CD163After sleep deprivation384 ng/mLStandard Deviation 250
Secondary

CD4+ T-cell Expression of HLA-DR and CD38

Percentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationCD4+ T-cell Expression of HLA-DR and CD38Baseline (Sleep repletion)8.14 % cellsStandard Deviation 9.09
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationCD4+ T-cell Expression of HLA-DR and CD38After sleep deprivation8.39 % cellsStandard Deviation 9.01
Secondary

CD8+ T-cell Expression of HLA-DR and CD38

Percentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationCD8+ T-cell Expression of HLA-DR and CD38Baseline (Sleep repletion)12.30 % cellsStandard Deviation 10.74
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationCD8+ T-cell Expression of HLA-DR and CD38After sleep deprivation13.17 % cellsStandard Deviation 11.06
Secondary

Flow Mediated Brachial Artery Dilation

Percent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point.

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationFlow Mediated Brachial Artery DilationBaseline (Sleep repletion)6.13 % changeStandard Deviation 2.68
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationFlow Mediated Brachial Artery DilationAfter sleep deprivation4.42 % changeStandard Deviation 3.22
Secondary

Monocyte Expression of IL6

Percentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationMonocyte Expression of IL6Baseline (Sleep repletion)84.6 % cellsStandard Deviation 13.6
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationMonocyte Expression of IL6After sleep deprivation89.1 % cellsStandard Deviation 8.3
Secondary

Monocyte Expression of TNF-alpha

Percentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

ArmMeasureGroupValue (MEAN)Dispersion
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationMonocyte Expression of TNF-alphaBaseline (Sleep repletion)52.0 % cellsStandard Deviation 37.4
Baseline (Sleep Replete State) Followed by 24 Hours of Sleep DeprivationMonocyte Expression of TNF-alphaAfter sleep deprivation64.1 % cellsStandard Deviation 32.4
Other Pre-specified

CD4+ T-cell Expression of CD39 and/or CD73

Percentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Other Pre-specified

CD8+ T-cell Expression of CD39 and/or CD73

Percentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Other Pre-specified

Plasma Adenosine

Plasma adenosine concentration

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Other Pre-specified

Plasma Inosine

Plasma inosine concentration

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Other Pre-specified

Urine 3'5'-cAMP

Urine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine

Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026